Compare TOON & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOON | ELOX |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Movies/Entertainment | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.0M | 43.8M |
| IPO Year | 2014 | N/A |
| Metric | TOON | ELOX |
|---|---|---|
| Price | $0.77 | $12.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 23.1K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.26 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,353,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.75 | N/A |
| 52 Week Low | $0.53 | $10.00 |
| 52 Week High | $1.29 | $14.28 |
| Indicator | TOON | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 46.33 | N/A |
| Support Level | $0.65 | N/A |
| Resistance Level | $0.90 | N/A |
| Average True Range (ATR) | 0.13 | 0.00 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 13.37 | 0.00 |
Kartoon Studios Inc is a media company developing, producing, marketing, and licensing branded animated entertainment properties and consumer products for media and retail distribution. Its portfolio features programming for toddlers to tweens, including the preschool properties Rainbow Rangers for Nick Jr. and Llama Llama for Netflix, Stan Lee's Superhero Kindergarten, Shaq's Garage, toddler brand Baby Genius, STEM-based series Thomas Edison's Secret Lab, Warren Buffett's Secret Millionaires Club, and the new preschool show, Stan Lee's Superhero Kindergarten. Its channel is available on television and mobile devices through distribution platforms, including Comcast, Cox, DISH, Sling TV, Apple TV, Roku, Android TV, Tubi, Xumo, and Amazon Fire.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.